Why Are Billionaire Investors Betting On The 2021 Mental Health Revolution?
Investors say this little-known sector feels exactly like CBD did in 2017. This new technology is making investors like Peter Thiel very excited.
See How Early "Mental Health Revolution" Investors

EDSA Insider Trading (Edesa Biotech)

Insider Ownership Percentage: 44.70%
Insider Buying (Last 12 Months): $54,425.00
Insider Selling (Last 12 Months): $57,942.00

Edesa Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at Edesa Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Edesa Biotech Share Price & Price History

Current Price: $5.42
Price Change: Price Increase of +0.13 (2.46%)
As of 06/23/2021 01:00 AM ET

This chart shows the closing price history over time for EDSA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Seattle Cannabis Company Capitalizes on Surging Demand
The increase in the number of states that permit recreational and medical use of cannabis means that growers, processors and manufacturers of cannabis products often can’t keep up with growing demand. One Seattle weed manufacturer is poised to sell products across state lines, easing shortages. This could drive the company’s shares sky-high.
Get all the details on this potential blockbuster!

Edesa Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2021Pardeep NijhawanCEOBuy2,000$5.23$10,460.00547,312View SEC Filing Icon  
3/25/2021Michael J BrooksPresidentBuy3,500$5.19$18,165.0013,241View SEC Filing Icon  
3/24/2021Pardeep NijhawanCEOBuy5,000$5.16$25,800.00542,312View SEC Filing Icon  
2/18/2021Frank R OakesDirectorSell7,992$7.25$57,942.00
5/27/2020Michael J BrooksPresidentBuy2,500$3.19$7,975.00
5/26/2020Pardeep NijhawanCEOBuy3,000$3.18$9,540.00537,312View SEC Filing Icon  
3/17/2020Pardeep NijhawanCEOBuy5,000$1.87$9,350.00537,312View SEC Filing Icon  
1/8/2020Der Velden Peter VanDirectorBuy140,625$3.20$450,000.008,524View SEC Filing Icon  
1/8/2020Michael J BrooksPresidentBuy1,827$4.11$7,508.971,827View SEC Filing Icon  
9/11/2019Frank R OakesDirectorSell1,809$5.72$10,347.48
See Full Table
Insider Trading at Edesa Biotech?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Edesa Biotech and related companies.

SEC Filings (Institutional Ownership Changes) for Edesa Biotech (NASDAQ:EDSA)

0.96% of Edesa Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at EDSA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Edesa Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/19/2021Virtu Financial LLC16,138$87K0.0%N/A0.122%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp15,349$83K0.0%N/A0.116%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC29,229$0.16M0.0%N/A0.222%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC74,100$0.32M0.0%N/A0.704%Search for SEC Filing on Google Icon
1/19/2021FNY Investment Advisers LLC75,000$0.32M0.1%-37.7%0.713%Search for SEC Filing on Google Icon
10/9/2020FNY Investment Advisers LLC120,407$0.97M0.4%N/A1.279%Search for SEC Filing on Google Icon
2/13/2020Renaissance Technologies LLC25,073$0.10M0.0%+59.2%0.334%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Read More on Edesa Biotech

Today's Range

Now: $5.42
Low: $5.28
High: $5.51

50 Day Range

MA: $5.88
Low: $4.93
High: $6.69

52 Week Range

Now: $5.42
Low: $4.05
High: $19.10

Volume

79,502 shs

Average Volume

447,522 shs

Market Capitalization

$71.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Who are the company insiders with the largest holdings of Edesa Biotech?

Edesa Biotech's top insider shareholders include:
  1. Pardeep Nijhawan (CEO)
  2. Michael J Brooks (President)
  3. Der Velden Peter Van (Director)
  4. Frank R Oakes (Director)

Who are the major institutional investors of Edesa Biotech?

Edesa Biotech's top institutional shareholders include:
  1. Geode Capital Management LLC — 0.22%
  2. Virtu Financial LLC — 0.12%
  3. Northern Trust Corp — 0.12%

Which institutional investors are buying Edesa Biotech stock?

In the last quarter, EDSA stock was bought by institutional investors including:
  1. Geode Capital Management LLC
  2. Virtu Financial LLC
  3. Northern Trust Corp
During the previous year, these company insiders have bought Edesa Biotech stock:
  1. Pardeep Nijhawan (CEO)
  2. Michael J Brooks (President)
  3. Der Velden Peter Van (Director)
Why Are Billionaire Investors Betting On The 2021 Mental Health Revolution?
Investors say this little-known sector feels exactly like CBD did in 2017. This new technology is making investors like Peter Thiel very excited.
See How Early "Mental Health Revolution" Investors